Search
Bevacizumab, olaparib i trabectedina per al tractament del càncer d'ovari epitelial avançat, trompa de Fal·lopi o peritoneal primari: informe d’avaluació de resultats
(2021)
Ovarian cancer is the fifth leading cause of cancer death in Europe in women and the leading cause of gynecological cancer. The initial treatment for ovarian cancer is platinum-based surgery and chemotherapy (QT). The ...
Tractament del carcinoma de cèl·lules renals avançat en segona línia: informe d’avaluació de resultats
(2021)
The data reported by prescribers have been selected for patients who have been treated in the Integral Health System of Catalonia (SISCAT) with axitinib, cabozantinib (anti-VEGF), nivolumab (anti-PDL1) or everolimus (mTOR ...
Omalizumab, mepolizumab, reslizumab i benralizumab per al tractament de l’asma greu no controlada en pacients adults: informe d’avaluació de resultats
(2021)
Asthma is a chronic inflammatory disease of an inflammatory nature involving immune system cells and immunomodulators, which cause an inflammatory response in the bronchi causing airflow obstruction. In Spain, the prevalence ...
Tractament del CPNM EFGR i T790M positiu amb osimertinib: informe d'avaluació de resultats
(2021-06)
Lung cancer (CP) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of CP for 2019 was 29,503 cases. CP continues to be the leading cause of cancer death in Spain in ...
Venetoclax en combinació amb rituximab en la leucèmia limfocítica crònica després de tractament previ
(2021-02-25)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in our environment in adulthood and accounts for 25-50% of all leukemias. The median age at diagnosis is 72 years and only 10% of patients are <55 years. It ...
Estudi d’utilització de medicaments per al tractament de la incontinència urinària: informe d’utilització de medicaments
(2021)
Urinary incontinence (UI) is a symptom of filling that is defined as the involuntary loss of urine produced during the bladder filling phase. Some authors nuance this definition by considering that these losses must be ...
Inhibidors del cotransportador sodi-glucosa tipus 2 (ISGLT2) i ISGLT2/metformina per al tractament de la diabetis mellitus tipus 2
(2021-03-03)
The term Diabetes Mellitus (DM) defines a series of metabolic disorders characterized by chronic hyperglycemia and disorders in the metabolism of carbohydrates, fats and proteins, as a result of defects in the secretion ...